- Home
- GUTS vs IKNA Comparison
GUTS vs IKNA Comparison
Compare GUTS & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- IKNA
- Stock Information
- Founded
- GUTS 2010
- IKNA 2016
- Country
- GUTS United States
- IKNA United States
- Employees
- GUTS N/A
- IKNA N/A
- Industry
- GUTS
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- IKNA Health Care
- Exchange
- GUTS NYSE
- IKNA Nasdaq
- Market Cap
- GUTS 58.8M
- IKNA 61.8M
- IPO Year
- GUTS 2024
- IKNA 2021
- Fundamental
- Price
- GUTS $1.68
- IKNA $1.32
- Analyst Decision
- GUTS Buy
- IKNA Strong Buy
- Analyst Count
- GUTS 1
- IKNA 1
- Target Price
- GUTS $10.00
- IKNA $4.00
- AVG Volume (30 Days)
- GUTS 938.9K
- IKNA 59.9K
- Earning Date
- GUTS 08-13-2025
- IKNA 08-07-2025
- Dividend Yield
- GUTS N/A
- IKNA N/A
- EPS Growth
- GUTS N/A
- IKNA N/A
- EPS
- GUTS N/A
- IKNA N/A
- Revenue
- GUTS $60,000.00
- IKNA N/A
- Revenue This Year
- GUTS N/A
- IKNA N/A
- Revenue Next Year
- GUTS N/A
- IKNA N/A
- P/E Ratio
- GUTS N/A
- IKNA N/A
- Revenue Growth
- GUTS N/A
- IKNA N/A
- 52 Week Low
- GUTS $0.87
- IKNA $0.97
- 52 Week High
- GUTS $4.92
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- GUTS 44.85
- IKNA 51.66
- Support Level
- GUTS $1.56
- IKNA $1.31
- Resistance Level
- GUTS $1.82
- IKNA $1.36
- Average True Range (ATR)
- GUTS 0.16
- IKNA 0.04
- MACD
- GUTS -0.05
- IKNA -0.01
- Stochastic Oscillator
- GUTS 16.92
- IKNA 13.61
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.